Simulated Comparison of the Pharmacodynamics of Ciprofloxacin and Levofloxacin Against Pseudomonas aeruginosa Using Pharmacokinetic Data from Healthy Volunteers and 2002 Minimum Inhibitory Concentration Data

• Published in: Clinical therapeutics Vol. 29; no. 7; pp. 1421 - 1427
• Main Authors: Burgess, David S., Hall, Ronald G.
• Format: Journal Article
• Language: English
• Published: Belle Mead, NJ EM Inc USA 01.07.2007; Excerpta Medica; Elsevier Limited
• Subjects: Anti-Bacterial Agents - blood; Anti-Bacterial Agents - pharmacokinetics; Anti-Bacterial Agents - pharmacology; Antibiotics; Antimicrobial agents; Biological and medical sciences; ciprofloxacin; Ciprofloxacin - blood; Ciprofloxacin - pharmacokinetics; Ciprofloxacin - pharmacology; Cystic fibrosis; Drug dosages; Drug stores; Drug therapy; Education; Female; Humans; Infectious diseases; Intensive care; Internal Medicine; Levofloxacin; Male; Medical Education; Medical sciences; Microbial Sensitivity Tests; Monte Carlo Method; Monte Carlo simulation; Nosocomial infections; Ofloxacin - blood; Ofloxacin - pharmacokinetics; Ofloxacin - pharmacology; Pharmacodynamics; Pharmacokinetics; Pharmacology. Drug treatments; Pharmacy; Pseudomonas aeruginosa; Pseudomonas aeruginosa - drug effects; Streptococcus infections; United States > US; Texas; Pseudomonas aeruginosa; levofloxacin; pharmacodynamics; ciprofloxacin; Pseudomonadales; Human; Levofloxacin; Pharmacodynamics; Healthy subject; Biological activity; Fluoroquinolone derivatives; Minimum inhibitory concentration; Bacteria; Pseudomonadaceae; Antibacterial agent; Ciprofloxacin; Pharmacokinetics; Quinolone derivatives; Comparative study

Background: Until the 2002 approval of levofloxacin 750 mg QD, ciprofloxacin was the fluoroquinolone of choice against Pseudomonas aeruginosa infections. Objective: This study evaluated the AUC:MIC ratios for ciprofloxacin 400 mg BID and TID and levofloxacin 750 mg QD, all administered intravenously...